Event Recap: NeuroStar Advanced Therapy Event

FDA cleared as a first-line add-on treatment for patients aged 15-21

On May 15, 2024, YRB attended a breakfast panel event hosted by EvolveMKD at The Standard Hotel in New York City.

The purpose of the event was to learn more about NeuroStar Advanced Therapy‘s breakthrough Transcranial Magnetic Stimulation (TMS) therapy’s FDA-clearance for treating depression in adolescents aged 15 and older.

Board-certified psychiatrist and TMS expert Dr. Kenneth Pages presented a live NeuroStar treatment demonstration on Chrissy, a 15-year-old advocate, and expertly explained the science behind TMS during the procedure.

President & CEO of Neuronetics Keith Sullivan kicked off the panel discussion with opening remarks.

“We are very proud that NeuroStar TMS system was cleared by the FDA as a First Line adjunct treatment for this group of young adults battling depression.”

The morning continued with a comprehensive discussion led by Megan Driscoll, CEO & Founder of EvolveMKD, where panelists like 15-year-old patient advocate Chrissy, her mother Patricia, and former MLB player and mental health advocate Drew Robinson shared their powerful experiences with NeuroStar, resonating deeply with the audience.

Their testimonies brought to life the impact major depressive disorder – and the right treatment – has on themselves, their families, and their communities.

Click here for additional information


Related Articles